{"id":986278,"date":"2026-07-29T07:11:24","date_gmt":"2026-07-29T11:11:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/"},"modified":"2026-07-29T07:11:24","modified_gmt":"2026-07-29T11:11:24","slug":"aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/","title":{"rendered":"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<ul type=\"disc\">\n<li>\n          <strong><br \/>\n            <em>141% year-over-year scan volume growth in first half of 2026<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li>\n          <strong><br \/>\n            <em>Reimbursement momentum in the U.K. translating into consistent scan volume growth <\/em><br \/>\n          <\/strong>\n        <\/li>\n<li>\n          <strong><br \/>\n            <em>Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage for Nociscan in the U.S.<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li>\n          <strong><br \/>\n            <em>Continued progress toward the CLARITY trial readout with the addition of multiple new trial sites<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li>\n          <strong><br \/>\n            <em>Strengthened intellectual property position with the addition of a new AI focused patent bringing total issued and pending patents to 65 worldwide<\/em><br \/>\n          <\/strong>\n        <\/li>\n<li>\n          <strong><br \/>\n            <em>Strong balance sheet with $16.3M cash and no debt as of June 30, 2026<\/p>\n<p><\/em><br \/>\n          <\/strong>\n        <\/li>\n<\/ul>\n<p>BROOMFIELD, Colo., July  29, 2026  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=4_OwrEk9lmzZ-tAqcvz4D_S9D-htzWNhtrolUKt8MgzI3lzXbzoU53onLvzE3BZwcVyuEZejt0XCOciZ3Le6nw==\" rel=\"nofollow\" target=\"_blank\">Aclarion, Inc<\/a>.,<strong>\u00a0(\u201cAclarion\u201d or the \u201cCompany\u201d) (Nasdaq: ACON, ACONW),<\/strong>\u00a0a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today the publication of a Shareholder Letter from Chief Executive Officer Brent Ness providing an update on the company\u2019s recent momentum and value creating priorities through the first half of 2026.<\/p>\n<p>\u201cThe first half of 2026 marked an important period of execution and momentum for Aclarion,\u201d said Brent Ness, Chief Executive Officer of Aclarion. \u201cScan volume growth in Q1 and Q2 reflected increasing physician engagement, strong execution by our commercial team, and growing confidence in Nociscan\u2019s ability to provide objective biochemical insights that support spine care decision making. The momentum is palpable as we are moving from early commercial validation toward a more scalable adoption phase. We believe Aclarion is well positioned to continue to advance our mission of building a scalable technology platform for chronic low back pain while creating long-term value for patients and shareholders.\u201d<\/p>\n<p>Key highlights include:<\/p>\n<ul type=\"disc\">\n<li>\n          <strong>141% year-over-year scan volume growth<\/strong> and\u00a0<strong>71% sequential scan volume growth\u00a0in first half of 2026<\/strong>, reflecting accelerating clinical adoption and broader integration into physician workflows.<\/li>\n<li>Continued expansion of Nociscan utilization across commercial accounts in the U.S. and U.K.<\/li>\n<li>\n          <strong>Reimbursement momentum in the U.K.<\/strong>, including reimbursement by Vitality, AXA, and Aviva, three of the four largest private insurers in the U.K.<\/li>\n<li>Partnered\u00a0with PRIA Healthcare to launch a <strong>U.S.-focused Market Access Program to establish payer coverage and expand patient access to Nociscan.<\/strong><\/li>\n<li>Continued\u00a0progress toward the\u00a0<strong>CLARITY trial readout<\/strong>, a key evidence-generation milestone for the Company.<\/li>\n<li>\n          <strong>Strengthened intellectual property position<\/strong>\u00a0with a newly issued AI patent and 65 total issued and pending patents worldwide.<\/li>\n<li style=\"margin-bottom:8pt\">\n          <strong>$16.3 million in cash and no debt as of June 30, 2026<\/strong>, supporting continued execution through key milestones <strong>with cash runway into the second half of 2027<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<p>The full CEO Shareholder Letter is available on the company\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=DSdvCjVszFzUB-Fb9iTqGmPIP_0LQ-MaTYkHOBPlGpWAdVRyICIbY3y-AswwtVX39A2wpsjEmLl-vwmmbRdDENRxNOCTbA2r0sml8SwYgvE=\" rel=\"nofollow\" target=\"_blank\">website<\/a>.<\/p>\n<p>For more News from Aclarion, please visit: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=jI0zyUtYB-mePZANA25abCBsutZL-AQ-efGP4SLiIfCkskiMQlTEA7FHXpPkKiNUtMBPtNffcVOtnrANjnsgPw==\" rel=\"nofollow\" target=\"_blank\"><strong>Latest News<\/strong><\/a><\/p>\n<p>To find a Nociscan center, view our site map\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=L_sJ_PJYT_BtYzLvLQzR7ojcXM_Y-vHPvO7kOBlWCZeaDknwulFMU9ZZ20R3JmTfUiBsZW26nZc74YRddcAFAunw8GH-YGVg0ewP2d0iHbrJ4p46VuG-jH2lTpcN-TnFVQ_XHbV-8RHwtTpVdLOKJI2iAqCZxq5-bWh_pZpTmgZmeKijqNH9vtBCVgnGsieCLX83MPf1JgZGhBXDJ4FzcQZAGSGiyxAgDK71U1Dgn-kiRF1hwNXIMirXG3Dw9b2mEEj_y8IbRA_465ToCn9lDKhty0vKHvH_qOlE1H0UkJuY_9IDKyubHuQlC9U-JyLzCyLTl_sHaitzvqiYfUimtk0VNr0bM6UEXKCI7g5shZzQN8lE_mR4rg-0VBiore1rg9gbl-rC36vHrREkFS3lPjrBaG9BLgQamzuHFOvIjlR1Oy8Qqzey4Z1y75IMLYqJgnJk3bKT0LxpGQ9uaxS80tlzn31BYfun1goBGKqCcoiwpiBVgPHOo8RvaSK3ONZz1lvmHpVD9EsQag-iMd8e9pQ1qGYo1EgRu53RQenpKrVfZE3exPWk4ypFLqo8jiiT0_3XuMhnRtx7sO70PXmHgmZWnlplui5Wo-YUwaKnEKDAafCMNNGfJv76Ft0bEwl98sWrY-0cozK9k6ak8UAF1iT447RnIIr9nhFyNLxpVaY4i65Kpc_K5AA9yVSLJjx8c5rkDiKAj4l_HgRQdMtfk4BQe1B1AjMh1P3uGoVnK4JZ0yWduxdVnh106Vx36OU-o0aSG3B2v2jgDoCB_HCLzvQeSvqmtbivjjl2jl8Lrjve3LM8Ajr_K-Gv7FyNDAgk9Futq73edrOmDIf17N2_xjT4l0lKeBjVERAiE4CMQ93he88yObX21tx4-sum1ytOqwREB7l_8iKXA50dY3xdfz4NwzkptZYUhjj8GBkdCyBAHzhMrxu_mmhYGQPu6ERg0DKJr0iLSFYjViI8e7RXpf3XMLmLs1aJ3eg5lUI1rmYoOIHlPseqJjVlcoBF-RQ9prJ-BNoyTLopH31gIU6uje1X6223zYvBKzTxrCHfyqTzFXX7Ijco8WSfdQx8PXbIawz2OoFHyzjQ9FCZrvlLF6Ftk50-bTjjm4tA9uXrclRpRv2SabKqtbex-gn8bOYmEF8VMw_dK2PNo9PYzc16ulYMGxy4MU-w5H1bG3LAmfVWCUsUtW0DphSlfb14I2BCdK7xjk_59HELionZtK6qepOyZnI6L0Eep-mj0H5cXE28kMUbS5X-CX-Nj8R12IcW-0Fv5sKZrQ2Ekhrm-Mg_tQ8LhatHv2XG4BNvxO9z1M2r4K8ndftf17G72I_4S_BkhZOCLjyvbBlEBy5fn4qhE8wXOR2zMZXrjjDxgSBiqPIZjAREkmSyRSRSxbfTmUscWUNylp6-q9NZY5D0gz4lotg0Km7eVXaNW-j420kqak7ZF1isILpkD-B2_mM6kreRrDvy8RhCDhuoqgG0atWVa0iLtnhROObK-x0VdQw8NvdFwCiW5r2XpzDuwd4CV9hr\" rel=\"nofollow\" target=\"_blank\">here<\/a>.<\/p>\n<p>For more information on Nociscan, please email: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=luokN2ZWBELVXY3g-bVyerhO_GrP8Tu6ofHr2sFK0Hs2C2ctSd4IgQnuhCDu9r1dhhbuwC2cHyjS-MZaf8wIkb_VMl-6IPy_2MaZ0t-KcIg=\" rel=\"nofollow\" target=\"_blank\">info@aclarion.com<\/a><\/p>\n<p>\n        <strong>About Aclarion, Inc.<\/strong>\n      <\/p>\n<p>Aclarion is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (\u201cMRS\u201d), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan, the first, evidence-supported, SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to indicate if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient\u2019s low back pain, giving physicians clarity to optimize treatment strategies. For more information, please visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=JEopBI2pNV-3NmuDK70rtTjkIrei2JmWYao7-QjN-WHwweLGFPOj1KdV5UVxdguSYSzDy-wdguoOUPoWn0l_DQCN2maxgeE06JJGNOEMUJE=\" rel=\"nofollow\" target=\"_blank\">www.aclarion.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 about the Company\u2019s current expectations about future results, performance, prospects and opportunities. Statements that are not historical facts, such as \u201canticipates,\u201d \u201cbelieves\u201d and \u201cexpects\u201d or similar expressions, are forward-looking statements. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the Company\u2019s current plans and expectations, as well as future results of operations and financial condition. Forward-looking statements in this release include, among others, statements regarding the enrollment of patients in our ongoing clinical trial, an initial interim data readout is expected later in 2026, having a cash runway into the second half of 2027, the potential benefits of our Nociscan technology, and the Company\u2019s plans for future regulatory and commercialization activities. These and other risks and uncertainties are discussed more fully in our filings with the Securities and Exchange Commission. Readers are encouraged to review the section titled \u201cRisk Factors\u201d in the Company\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, as well as other disclosures contained in the Prospectus and subsequent filings made with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date and the Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\u00a0<\/p>\n<p>\n        <strong>Investor Contacts:<\/strong>\n      <\/p>\n<p>Kirin M. Smith<br \/>PCG Advisory, Inc.<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8zOCKZ5iLnb1w0VG5jHP4hRnsJKwOpNwlOlzR4Q_FE-eMc4j8YnrDYZK41R_ynH3rYALQF9iTHwqXE2vxF5h1VL-ZRbDb7k7NsT6Yr-sasI=\" rel=\"nofollow\" target=\"_blank\">ksmith@pcgadvisory.com<\/a>\u00a0<\/p>\n<p>\n        <strong>Media Contacts:<\/strong>\n      <\/p>\n<p>Jennie Kim<br \/>SPRIG Consulting<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6aP1xaXO31n69o8QAWdi7WgBJSkd3LivxjvwmBfgbskYc_MxD3vbd0nY0s-JYhh3RsJyFADZxOalUxzU4VwvXtyhDkYLkLYm3DL_grz0UQRfXvW0ZVPpun4Yzl-Ne2bJ\" rel=\"nofollow\" target=\"_blank\">jennie@sprigconsulting.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MzNmNzVlZDEtYzcyYy00NmY3LThjYzctMzlmOTg1ZTNjYTZmLTUwMDEzMjI4Ni0yMDI2LTA3LTI5LWVu\/tiny\/Aclarion-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage for Nociscan in the U.S. Continued progress toward the CLARITY trial readout with the addition of multiple new trial sites Strengthened intellectual property position with the addition of a new AI focused patent bringing total issued and pending patents to 65 worldwide Strong balance sheet with $16.3M cash and no debt as of June 30, 2026 BROOMFIELD, Colo., July 29, 2026 (GLOBE NEWSWIRE) &#8212; Aclarion, Inc.,\u00a0(\u201cAclarion\u201d or the \u201cCompany\u201d) (Nasdaq: ACON, ACONW),\u00a0a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-986278","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.1 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage for Nociscan in the U.S. Continued progress toward the CLARITY trial readout with the addition of multiple new trial sites Strengthened intellectual property position with the addition of a new AI focused patent bringing total issued and pending patents to 65 worldwide Strong balance sheet with $16.3M cash and no debt as of June 30, 2026 BROOMFIELD, Colo., July 29, 2026 (GLOBE NEWSWIRE) &#8212; Aclarion, Inc.,\u00a0(\u201cAclarion\u201d or the \u201cCompany\u201d) (Nasdaq: ACON, ACONW),\u00a0a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms &hellip; Continue reading &quot;Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-29T11:11:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026\",\"datePublished\":\"2026-07-29T11:11:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/\"},\"wordCount\":895,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/\",\"name\":\"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==\",\"datePublished\":\"2026-07-29T11:11:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/","og_locale":"en_US","og_type":"article","og_title":"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 - Market Newsdesk","og_description":"141% year-over-year scan volume growth in first half of 2026 Reimbursement momentum in the U.K. translating into consistent scan volume growth Launched Market Access Program in partnership with PRIA Healthcare to secure insurance coverage for Nociscan in the U.S. Continued progress toward the CLARITY trial readout with the addition of multiple new trial sites Strengthened intellectual property position with the addition of a new AI focused patent bringing total issued and pending patents to 65 worldwide Strong balance sheet with $16.3M cash and no debt as of June 30, 2026 BROOMFIELD, Colo., July 29, 2026 (GLOBE NEWSWIRE) &#8212; Aclarion, Inc.,\u00a0(\u201cAclarion\u201d or the \u201cCompany\u201d) (Nasdaq: ACON, ACONW),\u00a0a commercial-stage healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms &hellip; Continue reading \"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-29T11:11:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026","datePublished":"2026-07-29T11:11:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/"},"wordCount":895,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/","name":"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==","datePublished":"2026-07-29T11:11:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc5OTk3OSM3NzQ4NDk3IzUwMDEzMjI4Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/aclarion-publishes-ceo-shareholder-letter-highlighting-progress-for-first-half-of-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Aclarion Publishes CEO Shareholder Letter Highlighting Progress for First Half of 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/986278","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=986278"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/986278\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=986278"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=986278"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=986278"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}